REFERENCES
- Pergolizzi JV Jr, Mercadante S, Virizuela Echaburu A, Van den Eynden B, de Faría Fragoso RM, Mordarski S, Lybaert W, Beniak J, Orońska A, Slama O. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. Curr Med Res Opin 2009;25:1517–1528.
- World Health Organization. Cancer Pain Relief With A Guide to Opioid Availability, 2nd edition. Geneva: World Health Organization. 1996.
- American Geriatrics Society Panel on the Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Ger Soc 2009;57;1331–1346.
- Benomar S, Boutayeb S, Lalyac I, Errihani H, Hassam B, El Gueddari BK. Treatment and prevention of acute radiation dermatitis. Cancer Radiother 2010;14:213–216.
- Bolderston A, Lloyd NS, Wong RK, Holden L, Robb-Blenderman L. The prevention and management of acute skin reactions related to radiation therapy: a systematic review and practice guideline. Support Care Cancer 2006;14:802–817.
- Epstein JB, Schubert MM. Oropharyngeal mucositis in cancer therapy. Review of pathogenesis, diagnosis, and management. Oncology (Williston. Park) 2003;17:1767–1779.
- Scully C, Epstein J, Sonis S. Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy. Part 2: diagnosis and management of mucositis. Head Neck 2004;26:77–84.
- Murphy BA, Gilbert J. Dysphagia in head and neck cancer patients treated with radiation: assessment, sequelae, and rehabilitation. Semin Radiat Oncol 2009;19:35–42.
- Berner B, John VA. Pharmacokinetic characterisation of transdermal delivery systems. Clin Pharmacokinet 1994;26: 121–134.
- Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008;8:287–313.
- Pergolizzi J, Aloisi AM, Dahan A, Filitz J, Langford R, Likar R, Mercadante S, Morlion B, Raffa RB, Sabatowski R, Sacerdote P, Torres LM, Weinbroum AA. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract 2010;10:428–450.
- Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS [internet]; 25 September 2008 [accessed 26 July 2012]. Available from: http://ctep.cancer.gov.
- Grünenthal GmbH. Transtec 35, 52.5 and 70 micrograms transdermal patch –summary of product characteristics (revised October 2011). [accessed 26 July 2012]. Available from: http://www.grunenthal.com/cms/cda/_common/inc/display_file.jsp?fileID=9400035.
- Porreca F, Ossipov MH. Nausea and vomiting side effects with opioid analgesics during treatment of chronic pain: mechanisms, implications, and management options. Pain Med 2009;10:654–662.